Logo image of VAXX

VAXXINITY INC-A (VAXX) Stock Fundamental Analysis

NASDAQ:VAXX - Nasdaq - US92244V1044 - Common Stock - Currency: USD

0.1111  -0.02 (-15.26%)

After market: 0.1107 0 (-0.36%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to VAXX. VAXX was compared to 557 industry peers in the Biotechnology industry. Both the profitability and financial health of VAXX have multiple concerns. VAXX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VAXX had negative earnings in the past year.
VAXX had a negative operating cash flow in the past year.
VAXX had negative earnings in each of the past 5 years.
VAXX had a negative operating cash flow in each of the past 5 years.
VAXX Yearly Net Income VS EBIT VS OCF VS FCFVAXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -128.51%, VAXX is not doing good in the industry: 84.27% of the companies in the same industry are doing better.
VAXX has a Return On Equity of -424.66%. This is in the lower half of the industry: VAXX underperforms 76.92% of its industry peers.
Industry RankSector Rank
ROA -128.51%
ROE -424.66%
ROIC N/A
ROA(3y)-93.82%
ROA(5y)-250%
ROE(3y)-217.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VAXX Yearly ROA, ROE, ROICVAXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VAXX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VAXX Yearly Profit, Operating, Gross MarginsVAXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -50K -100K -150K

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for VAXX has been increased compared to 1 year ago.
Compared to 1 year ago, VAXX has a worse debt to assets ratio.
VAXX Yearly Shares OutstandingVAXX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
VAXX Yearly Total Debt VS Total AssetsVAXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -15.07, we must say that VAXX is in the distress zone and has some risk of bankruptcy.
VAXX has a Altman-Z score of -15.07. This is amonst the worse of the industry: VAXX underperforms 84.10% of its industry peers.
A Debt/Equity ratio of 0.99 indicates that VAXX is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.99, VAXX is not doing good in the industry: 78.29% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF N/A
Altman-Z -15.07
ROIC/WACCN/A
WACCN/A
VAXX Yearly LT Debt VS Equity VS FCFVAXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

VAXX has a Current Ratio of 1.89. This is a normal value and indicates that VAXX is financially healthy and should not expect problems in meeting its short term obligations.
VAXX has a worse Current ratio (1.89) than 76.58% of its industry peers.
VAXX has a Quick Ratio of 1.89. This is a normal value and indicates that VAXX is financially healthy and should not expect problems in meeting its short term obligations.
VAXX has a Quick ratio of 1.89. This is in the lower half of the industry: VAXX underperforms 74.87% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.89
VAXX Yearly Current Assets VS Current LiabilitesVAXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

VAXX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.07%, which is quite impressive.
EPS 1Y (TTM)25.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

VAXX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.26% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y17.39%
EPS Next 2Y7.34%
EPS Next 3Y3.5%
EPS Next 5Y3.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VAXX Yearly Revenue VS EstimatesVAXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2026 2027 2028 2029 2030 50M 100M 150M 200M
VAXX Yearly EPS VS EstimatesVAXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VAXX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VAXX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VAXX Price Earnings VS Forward Price EarningsVAXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VAXX Per share dataVAXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.34%
EPS Next 3Y3.5%

More info and screens

0

5. Dividend

5.1 Amount

VAXX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VAXXINITY INC-A

NASDAQ:VAXX (5/8/2024, 8:24:57 PM)

After market: 0.1107 0 (-0.36%)

0.1111

-0.02 (-15.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2024-05-13/bmo
Earnings (Next)08-07 2024-08-07/amc
Inst Owners2.07%
Inst Owner Change-99.95%
Ins Owners56.51%
Ins Owner Change0%
Market Cap14.08M
Analysts87.5
Price Target15.3 (13671.38%)
Short Float %0.35%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)36.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB 1.05
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -128.51%
ROE -424.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-93.82%
ROA(5y)-250%
ROE(3y)-217.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.89
Altman-Z -15.07
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)89.08%
Cap/Depr(5y)94.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.03%
EPS Next Y17.39%
EPS Next 2Y7.34%
EPS Next 3Y3.5%
EPS Next 5Y3.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-78.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.34%
OCF growth 3YN/A
OCF growth 5YN/A